In this article, we discuss the 5 stocks receiving price-target hike from Wall Street analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts See Upside Potential for 10 Stocks with Rising Price Targets.
05. Akero Therapeutics, Inc. (NASDAQ:AKRO)
Upside Potential: 24%
On September 5, JPMorgan Chase & Co. made a significant adjustment in evaluating Akero Therapeutics, Inc. (NASDAQ:AKRO). JPMorgan Chase took a noteworthy step by increasing the company’s price target from $49.00 to a more optimistic target of $62.00. This represents a 24% upside potential for Akero Therapeutics, Inc. (NASDAQ:AKRO) stock compared to its current price of $49.97. Importantly, JPMorgan Chase & Co. retained its “Overweight” rating for Akero Therapeutics, Inc. (NASDAQ:AKRO). This move underscores JPMorgan Chase’s continued confidence in Akero Therapeutics, Inc. (NASDAQ:AKRO). It conveys their belief that Akero Therapeutics, Inc. (NASDAQ:AKRO) stock not only justifies its existing “Overweight” rating but also possesses the potential to reach the newly established target of $62.00.
04. Permian Resources Corporation (NYSE:PR)
Upside Potential: 37%
On September 5, Stifel Nicolaus upheld its current Permian Resources Corporation (NYSE:PR) evaluation. They maintained a “Buy” rating for the company’s stock. However, there’s a notable adjustment in their price target, which has been revised from $18.00 to a more optimistic range of $20.00, reflecting a significant 37% upside potential compared to its current market price, which is $14.60. In practical terms, the “Buy” rating suggests that Stifel Nicolaus anticipates Permian Resources Corporation (NYSE:PR) stock to outperform the market or other comparable investments. The updated price target of $20.00 indicates Stifel Nicolaus’s belief that Permian Resources Corporation (NYSE:PR) stock has the potential to reach this value within a specified timeframe. This upward adjustment in the price target underscores Stifel Nicolaus’s positive outlook on Permian Resources Corporation (NYSE:PR) growth prospects while maintaining a bullish stance on the stock.
03. Biogen Inc. (NASDAQ:BIIB)
Upside Potential: 43%
Biogen Inc. (NASDAQ:BIIB) is an American firm that makes and sells treatments for nervous system disorders. The firm has beaten analyst EPS estimates in all four of its latest quarters. On September 5, Morgan Stanley increased its price target for Biogen Inc. (NASDAQ:BIIB) from $363.00 to $381.00 while maintaining an “Overweight” rating for the company’s shares. Despite the stock’s marginal decrease of 0.3% in share price on September 5, the new target reflects Morgan Stanley’s positive outlook on Biogen Inc. (NASDAQ:BIIB). This adjustment underscores Morgan Stanley’s belief in the growth potential of Biogen. It suggests that Biogen Inc. (NASDAQ:BIIB) may not only justify its existing “Overweight” rating but also potentially reach the newly established target of $381.00, according to Morgan Stanley’s analysis.
02. ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)
Upside Potential: 44%
On September 5, Citigroup increased its price target for ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) from $8.00 to $13.00, indicating a bullish sentiment despite the stock experiencing a 3.0% decrease. The new price target reflects a significant 44% upside potential for the stock. The new target reflects Citigroup’s optimistic outlook on ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC). This adjustment signals Citigroup’s belief that ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) may not only warrant a more favorable valuation but potentially reach the newly established target of $13.00. It suggests that Citigroup views the company’s prospects positively, despite the short-term market fluctuations.
01. Nexstar Media Group, Inc. (NASDAQ:NXST)
Upside Potential: 64%
On September 5, Rosenblatt Securities raised its price target for Nexstar Media Group, Inc. (NASDAQ:NXST) from $228.00 to $230.00, maintaining its “Buy” rating for its shares. The updated target price suggests a substantial 64% potential for the stock to increase in value. Despite the stock experiencing a minor decrease of 0.9%, this upward adjustment reflects Rosenblatt Securities’ optimistic outlook on Nexstar Media Group, Inc. (NASDAQ:NXST). The revised price target indicates Rosenblatt Securities’ confidence in Nexstar Media Group, Inc. (NASDAQ:NXST), suggesting that the company may not only justify its existing “Buy” rating but potentially reach the newly established target of $230.00. This adjustment underscores their positive sentiment regarding Nexstar Media Group, Inc. (NASDAQ:NXST) future performance.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out our articles on 10 Jim Cramer Stock Picks this Week and Jim Chanos’ 10 Short Positions in 2023.
